Bladder Cancer
Investigation and management of bladder cancer.
Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
Clinical Guidelines
Bladder Cancer: ESMO Clinical Practice Guidelines
National
EAU Guidelines on Muscle-invasive and Metastatic Bladder CancerNational
EAU Guidelines on Non-muscle-invasive Bladder CancerNational
NICE guideline [NG12]: Suspected cancer: recognition and referralNational
NICE guideline [NG2]: Bladder CancerNational
NICE guideline [NG2]: Bladder cancer: diagnosis and managementNational
Bladder Cancer Treatment (PDQ®) – Health Professional VersionLocal
Bladder Cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upLocal
Bladder Cancer: Non-Muscle Invasive Guideline - American Urological Association (AUA)Local
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 AmendmentLocal
EAU Guidelines on Muscle-Invasive and Metastatic Bladder CancerLocal
EAU Guidelines on Non-Muscle-Invasive Bladder CancerLocal
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder CancerLocal
ESMO Clinical Practice Guideline: Bladder CancerLocal
ESMO Consensus Recommendations: Bladder CancerLocal
FDA Guidance: Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for TreatmentLocal
Guideline on Muscle-Invasive and Metastatic Bladder Cancer: American Society of Clinical Oncology (ASCO) Endorsement of the EAU GuidelineLocal
NCCN Clinical Practice Guidelines in Oncology: Bladder CancerLocal
NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version: 2.2025Local
NICE Guideline, No. 2: Bladder Cancer. Diagnosis and ManagementLocal
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer (AUA/ASCO/ASTRO/SUO Guideline)Local